Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | DRD1 | P21728 | 2/20 | 0.64 |
| ▸ | DRD3 | P35462 | 2/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397269 | 0.93 | ALDH1A1 (0.72) | ALDH1A1KMT2ACNR1CNR2MEN1 | |
| SCHEMBL13400384 | 0.89 | KMT2A (0.64) | CYP2D6ALDH1A1KMT2ACNR1CNR2 | |
| SCHEMBL3394420 | 0.89 | ALDH1A1 (0.67) | ALDH1A1KMT2ACNR1CNR2MEN1 | |
| SCHEMBL3395078 | 0.89 | ALDH1A1 (0.67) | ALDH1A1KMT2ACNR1CNR2MEN1 | |
| SCHEMBL8203698 | 0.89 | ALDH1A1 (0.67) | ALDH1A1KMT2ACNR1CNR2MEN1 | |
| SCHEMBL3395664 | 0.89 | ALDH1A1 (0.67) | ALDH1A1KMT2ACNR1CNR2MEN1 | |
| SCHEMBL3397990 | 0.87 | NPSR1 (0.71) | ALDH1A1KMT2ACNR1CNR2MEN1 | |
| SCHEMBL13433213 | 0.86 | KMT2A (0.61) | CYP2D6ALDH1A1KMT2ACNR1CNR2 | |
| SCHEMBL8202548 | 0.86 | ALDH1A1 (0.67) | ALDH1A1KMT2ACNR1CNR2MEN1 | |
| SCHEMBL8203934 | 0.86 | ALDH1A1 (0.67) | ALDH1A1KMT2ACNR1CNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | claimed |
| EP-2074105-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-07-01 | — | — | EP | claimed |
| WO-2008043183-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-04-17 | — | — | WO | claimed |
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1B, CACNA1F | CHRM2 350/4885ADRA2A 256/4885CHRM1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.